knowledge -WSS

knowledge

author：leisure time 2025-09-30 16:26:59 - browse：642

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s ALS treatment — the latest potential turning point for a drug that has seen its share of ups and downs with regulatory bodies.

In June, a European Medicines Agency committee issued a negative review of Amylyx’s drug, called Albrioza, and cast doubt on whether it had demonstrated effectiveness in its pivotal study. That would have almost certainly led to a rejection by regulators, but Amylyx requested what’s called a re-examination of the opinion. On Tuesday, the EMA held a meeting on the appeal, and a decision is expected in the coming weeks.

“There are patients who are dying and they really want access to the drug,” said Evy Reviers, the chairwoman of the European Organization for Professionals and Patients with ALS, whose father has the neurological disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Readout Newsletter: Merck, Vertex, and Viking updates

WSS

How I helped Pfizer think through the ethics of Viagra

The Readout: Lenmeldy, GLP

Merck drug for rare lung condition set for approval in U.S.

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Covid vaccine financial winners and losers, from Pfizer to Novavax

Decaf coffee targeted by food safety group under obscure FDA rule

leisure time

knowledge

knowledge

Moonlake's readout produced a cash windfall. Risks remain

Late stage cancers on the rise after pandemic delayed screenings

Peter Hotez and the public health issue of online harassment

Food as medicine: Medically tailored meals may get standardized

Apple is now the first public company to be valued at $3 trillion

Heart disease in astronauts blamed on cosmic radiation

Drug repurposing or repositioning? The language matters

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

After affirmative action ruling, medical educators look to 'holistic review'

When waiting feels immoral: Empathy in the emergency department

focus

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Decaf coffee targeted by food safety group under obscure FDA rule

FDA's naming rule on biosimilars has undermined competition

H.R. 3 is the wrong path to lower drug costs

There's no autism epidemic. It's an autism diagnosis epidemic

It costs an awful lot of money to give away a kidney

entertainment

Wikipedia

explore

focus